Abdelaziz Toumi is the CEO of Lupin Manufacturing Solutions

Global pharma major Lupin Limited (Lupin) announced the appointment of Abdelaziz Toumi (Abdel) as the Chief Executive Officer of its newly formed subsidiary, Lupin Manufacturing Solutions (LMS) with effect from June 17, 2024. LMS is engaged in the development, manufacture, and sale of Active Pharmaceutical Ingredients and is starting to build its Contract Development and Manufacturing Operations (CDMO) business.

Commenting on the appointment, Lupin’s Managing Director, Nilesh Gupta, said, “We are delighted to welcome Abdel to our team. He brings a wealth of knowledge and experience in the API CDMO space and will be instrumental in establishing LMS as a trusted and preferred partner for our global customers.”

Read the full statement here.

About Abdelaziz Toumi 

Abdel is a seasoned leader with a blend of scientific and commercial skills, bringing over two decades of rich experience in the biotech, pharma, and CDMO sectors. His career spans Europe, North America, and Asia, where he has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma.

In these roles, Abdel was responsible for driving growth, innovation, and operational excellence. He holds a Doctorate in Chemical Engineering and a Master’s degree in Business Administration from the University of Southern Queensland. Although based in Switzerland, Abdel will spend considerable time in India to oversee LMS operations.

About Lupin Limited

Lupin Limited is a global pharmaceutical company known for its high-quality generic and branded formulations, biotechnology products, and Active Pharmaceutical Ingredients (APIs). The company has a strong presence in over 100 countries, including the United States, India, Japan, and Europe.

With a commitment to innovation and excellence, Lupin continues to be a leader in the pharmaceutical industry, delivering advanced healthcare solutions worldwide.